We protect your health through science

Investigation

Serology

Research Lines

Content with Investigacion Neumococos .

Neumococos

Vigilancia epidemiológica de los serotipos y genotipos que causan enfermedad neumocócica invasiva (ENI) en España. Caracterización molecular de factores de virulencia de neumococo. Identificación y caracterización de proteínas de neumococo candidatas a vacuna. Evaluación de mecanismos de evasión de la respuesta inmune en Streptococcus pneumoniae. Impacto de los biofilms bacterianos en la persistencia del tracto respiratorio. Mecanismos de cronicidad de aislados clínicos de neumococo en pacientes con enfermedad pulmonar obstructiva crónica.

Research projects

Content with Investigacion Neumococos .

1: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones en pacientes con fibrosis quística provocadas por los patógenos Pseudomonas aeruginosa y Staphylococcus aureus: CF-TREAT

Referencia: CPP2022-009574 / MPY 375/23

Agencia Financiadora: Agencia Estatal de Investigación. MICINN.

Fecha Inicio:    01/12/2023
Fecha Fin:    30/11/2026
Financiación: 238.938 Euros
Investigadores principales: Roberto Díez Martínez, José E. Yuste Lobo y Pilar García Suárez

 

2: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones humanas producidas por Enterococcus faecium resistente a vancomicina (ANTI‐VRE).
Proyecto CPP2021-009054 financiado por MICIU/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR

Investigadores principales: Roberto Díez Martínez, Jose Yuste Lobo y Mirian Domenech

Periodo: 18/11/2022 - 17/11/2025

Cuantía total: 231.455 €

3: Título del proyecto: Mecanismos de virulencia en patógenos respiratorios.
Entidad financiadora: Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (Convocatoria «Proyectos I+D+I» 2020 - Modalidades «Retos Investigación» y «Generación de Conocimiento»). Referencia: PID2020-119298RB-I00

Investigador principal: Jose Yuste Lobo

Periodo: 01/09/2021 - 30/08/2024

Cuantía total: 121.000 €

4: Título del proyecto: Efectividad de la vacuna antineumocócica conjugada 13-valente frente a la hospitalización por neumonía adquirida en la comunidad en adultos de 60 años o mayores, mediante un estudio de casos y controles modificado. Estudio CIBELES.

Investigadores principales: Jose Yuste Lobo y Ángel Gil de Miguel
Entidad financiadora: PFIZER. Referencia: MVP 249/20
Periodo: 23/02/2021 - 22/02/2025
Cuantía total: 168.000 €

5: Título del proyecto: Evolution of Invasive Pneumococcal Disease in Spain with special focus on the pathogenesis of serotypes 3, 8, 11A, 19A, 22F and 33F. Investigadores principales: Jose Yuste Lobo y Mirian Domenech.
Entidad financiadora: Merck Sharp & Dohme USA. Referencia: MVP 132/21
Período: 16/06/2021 - 15/12/2023
Cuantía total: 157.448€

6: Título del proyecto: Mecanismos de patogenicidad y protección en bacterias Gram-positivas causantes de enfermedad respiratoria y bacteriemia
Investigador principal: Jose Yuste Lobo
Entidad financiadora: MINECO. Referencia: SAF2017-83388-R
Periodo: 31/12/2017 - 30/06/2021
Cuantía total: 145.200 €

7: Título del proyecto: Characterization of susceptibility to cefditoren investigating penicillin resistant clinical isolates of Streptococcus pneumoniae.
Investigadores: Jose Yuste Lobo y Mirian Domenech Lucas
Entidad financiadora: Tedec Meiji Farma, S.A. Referencia: MVP 119/20
Periodo: 11/07/2020 – 10-07-2022
Cuantía total: 76.517 €

8: Título del proyecto: Impact of clinical isolates of serotypes 22F and 33F in the epidemiology and pathogenesis of Streptococcus pneumoniae.
Investigador principal: Jose Yuste Lobo
Entidad financiadora: Merck Sharp & Dohme España, S.A. Referencia: MVE 213/18
Periodo: 10/05/2018 - 30/05/2021
Cuantía total: 157.604 €

Publications

Sort
Category

Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain

9. M Cabrerizo*, D Tarragó, C Muñóz-Almagro, E del Amo, M Domínguez-Gil, JM Eiros, I López-Miragaya, C Pérez, J Reina, A Otero, I González, JE Echevarría, G Trallero. Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth diease in Spain. Clin Microbiol Infect; 20: O150–O156 (2014).

PUBMED DOI

Going beyond serology for stratifying the risk of CMV infection in transplant recipients

Navarro D, Fernández-Ruiz M, Aguado JM, Sandonís V, Pérez-Romero P*. Going beyond serology for stratifying the risk of CMV infection in transplant recipients. Rev Med Virol. 2019 Jan;29(1):e2017.

PUBMED DOI

Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study. Clin Microbiol Infect.

Molina-Ortega A, Martín-Gandul C, Mena-Romo JD, Rodríguez-Hernández MJ, Suñer M, Bernal C, Sánchez M, Sánchez-Céspedes J, Pérez Romero P*, Cordero E. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study. Clin Microbiol Infect. 2019 Jun;25(6):753-758.

PUBMED DOI

Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: A pilot study.

Martín-Gandul C, Pérez-Romero P*, Mena-Romo D, Molina-Ortega A, González-Roncero FM, Suñer M, Bernal G, Cordero E; Spanish Network for Research in Infectious Diseases (REIPI). Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: A pilot study. Transpl Infect Dis. 2018 Jun;20(3):e12883.

PUBMED DOI

Content with Investigacion Genética Bacteriana .

List of staff

Additional Information

The main objective of the Serology Laboratory is to provide services to centers of the National Health System, through the offer in the service portfolio of the National Microbiology Center, in carrying out diagnosis and reference through the detection of antibodies, both for primary diagnosis and for reference activities.

For this, it has the appropriate serological methodologies, many of them accredited by ENAC in accordance with the ISO15189 standard. Conducts test validation studies through collaboration agreements with private entities.

Participates in seroprevalence studies, carried out through management assignments with the Ministry of Health and with the Public Health authorities of different autonomous communities.

On the other hand, it participates in research projects in relation to infectious diseases, in recent years on neurological diseases, on emerging diseases and on the viruses included in the MMR vaccine.

The main objective of the Serology Laboratory is to provide services to centers of the National Health System, through the offer in the service portfolio of the National Microbiology Center, in carrying out diagnosis and reference through the detection of antibodies, both for primary diagnosis and for reference activities.

For this, it has the appropriate serological methodologies, many of them accredited by ENAC in accordance with the ISO15189 standard. Conducts test validation studies through collaboration agreements with private entities.

Participates in seroprevalence studies, carried out through management assignments with the Ministry of Health and with the Public Health authorities of different autonomous communities.

On the other hand, it participates in research projects in relation to infectious diseases, in recent years on neurological diseases, on emerging diseases and on the viruses included in the MMR vaccine.

Content with Investigacion Genética Bacteriana .